Home » RANBAXY AND NIPPON CHEMIPHAR TO LAUNCH GENERICS IN JAPAN
RANBAXY AND NIPPON CHEMIPHAR TO LAUNCH GENERICS IN JAPAN
India-based Ranbaxy Laboratories has announced that Nihon Pharmaceutical Industry, a joint venture between Ranbaxy and Japanese company Nippon Chemiphar, has successfully launched Clarithromycin 50-mg and 200-mg tablets and Terbinafine 125-mg tablets in Japan.
Clarithromycin, an antibiotic, and Terbinafine, an anti-fungal will be sold in Japan under the Nihon Pharmaceutical label.
Ranbaxy entered the Japanese market in 2002 through a strategic alliance with
Nippon Chemiphar. In July 2005, the joint venture introduced its first co-developed
product, Vogseal (generic Voglibose), for the treatment of diabetes.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct